Giovanna Carello‐Collar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giovanna Carello‐Collar has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Eduardo Rigon Zimmer
Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
13 shared publications - Tharick Ali Pascoal
Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
7 shared publications - Bruna Bellaver
Department of Psychiatry, School of Medicine, University of Pittsburgh, PA
5 shared publications - Marco Antônio De Bastiani
Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
5 shared publications - Pedro Rosa-Neto
Montreal Neurological Institute, McGill University Health Centre, Montréal, Québec, Canada
5 shared publications - Christian Limberger
Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS); Porto Alegre, Brazil
4 shared publications
Latest Publications
- Open Access
- 21 July 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (7) , e70160
Dissection of Neurochemical Pathways Across Complexity and Scale
The field of Neurochemistry spent decades trying to understand how the brain works, from nano to macroscale and across diverse species. Technological advancements over the years allowed researchers to better visualize and understand the cellular processes underpinning central nervous system (CNS) function. This review provides an overview of how novel models, and tools have allowed Neurochemistry researchers to investigate new and exciting research questions. We discuss the merits and demerits of different in vivo models (e.g., Caenorhabditis elegans, Drosophila melanogaster, Ratus norvegicus, and Mus musculus) as well as in vitro models (e.g., primary cells, induced pluripotent stem cells, and immortalized cells) to study Neurochemical events. We also discuss how these models can be paired with cutting‐edge genetic manipulation (e.g., CRISPR‐Cas9 and engineered viral vectors) and imaging techniques, such as super‐resolution microscopy and new biosensors, to study cellular processes of the CNS. These technological advancements provide new insight into Neurochemical events in physiological and pathological contexts, paving the way for the development of new treatments (e.g., cell and gene therapies or small molecules) that aim to treat neurological disorders by reverting the CNS to its homeostatic state. image
- 21 July 2025
- Published by Wiley in Journal of Neurochemistry
- Vol. 169 (7) , e70160
Open AccessDissection of Neurochemical Pathways Across Complexity and Scale
The field of Neurochemistry spent decades trying to understand how the brain works, from nano to macroscale and across diverse species. Technological advancements over the years allowed researchers to better visualize and understand the cellular processes underpinning central nervous system (CNS) function. This review provides an overview of how novel models, and tools have allowed Neurochemistry researchers to investigate new and exciting research questions. We discuss the merits and demerits of different in vivo models (e.g., Caenorhabditis elegans, Drosophila melanogaster, Ratus norvegicus, and Mus musculus) as well as in vitro models (e.g., primary cells, induced pluripotent stem cells, and immortalized cells) to study Neurochemical events. We also discuss how these models can be paired with cutting‐edge genetic manipulation (e.g., CRISPR‐Cas9 and engineered viral vectors) and imaging techniques, such as super‐resolution microscopy and new biosensors, to study cellular processes of the CNS. These technological advancements provide new insight into Neurochemical events in physiological and pathological contexts, paving the way for the development of new treatments (e.g., cell and gene therapies or small molecules) that aim to treat neurological disorders by reverting the CNS to its homeostatic state. image
- Open Access
- 1 April 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-10
Autoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue
Background: Amyloid-β imaging through positron emission tomography (PET) has significantly transformed Alzheimer’s disease (AD) research. [11C]PiB has been widely used for imaging β-amyloid plaques due to its high affinity and selectivity for amyloid deposits. [18F]AZD4694 is a more recently developed amyloid-PET imaging agent, which structurally resembles PiB and has less non-specific binding in the white matter than other 18F-labeled compounds. The purpose of this study is to compare the in vitro binding properties of the amyloid-PET radiotracers [11C]PiB and [18F]AZD4694 in post-mortem human brain tissue. Total binding was assessed by autoradiography in prefrontal, inferior parietal, posterior cingulate cortices and hippocampal sections of healthy control (HC) and AD autopsy-confirmed brain tissues. Furthermore, the displacement of [18F]AZD4694 by unlabeled PiB was evaluated in the above-mentioned sections of AD brain tissues. Results: For both radiotracers, we found significant differences (p < 0.0001) between HC and AD tissues binding in the prefrontal cortex ([11C]PiB Cohen’s d = 3.424, [18F]AZD4694 Cohen’s d = 5.070), inferior parietal cortex ([11C]PiB Cohen’s d = 3.156, [18F]AZD4694 Cohen’s d = 3.959), posterior cingulate cortex ([11C]PiB Cohen’s d = 1.781, [18F]AZD4694 Cohen’s d = 3.434), and hippocampus ([11C]PiB Cohen’s d = 1.320, [18F]AZD4694 Cohen’s d = 3.696). Higher binding was detected for [18F]AZD4694 compared to [11C]PiB in AD prefrontal, inferior parietal and posterior cingulate cortices, while binding in the hippocampus was comparable for both radioligands. Strong correlations between [18]AZD4694 and [11C]PiB were found in the prefrontal (R = 0.959, p < 0.0001), inferior parietal (R = 0.893, p < 0.0001), posterior cingulate (R = 0.838, p = 0.0006) cortices and hippocampus (R = 0.750, p < 0.0001). Bland–Altman analyses revealed strong agreement between [11C]PiB and [18F]AZD4694 in the prefrontal, inferior parietal, and posterior cingulate cortices, but lower agreement in the hippocampus. Displacement studies confirmed high binding affinity of PiB in all tissues, indicating that both amyloid-PET agents compete for the same binding sites. Conclusions: This head-to-head study provides evidence that while [18F]AZD4694 and [11C]PiB bindings are highly correlated with both tracers competing for the same binding sites, [18F]AZD4694 has a slightly higher effect size when comparing between neuropathologically-confirmed AD and HC brain tissues.
- 1 April 2025
- Published by Springer Nature in EJNMMI Research
- Vol. 15 (1) , 1-10
Open AccessAutoradiographic comparison between [11C]PiB and [18F]AZD4694 in human brain tissue
Background: Amyloid-β imaging through positron emission tomography (PET) has significantly transformed Alzheimer’s disease (AD) research. [11C]PiB has been widely used for imaging β-amyloid plaques due to its high affinity and selectivity for amyloid deposits. [18F]AZD4694 is a more recently developed amyloid-PET imaging agent, which structurally resembles PiB and has less non-specific binding in the white matter than other 18F-labeled compounds. The purpose of this study is to compare the in vitro binding properties of the amyloid-PET radiotracers [11C]PiB and [18F]AZD4694 in post-mortem human brain tissue. Total binding was assessed by autoradiography in prefrontal, inferior parietal, posterior cingulate cortices and hippocampal sections of healthy control (HC) and AD autopsy-confirmed brain tissues. Furthermore, the displacement of [18F]AZD4694 by unlabeled PiB was evaluated in the above-mentioned sections of AD brain tissues. Results: For both radiotracers, we found significant differences (p < 0.0001) between HC and AD tissues binding in the prefrontal cortex ([11C]PiB Cohen’s d = 3.424, [18F]AZD4694 Cohen’s d = 5.070), inferior parietal cortex ([11C]PiB Cohen’s d = 3.156, [18F]AZD4694 Cohen’s d = 3.959), posterior cingulate cortex ([11C]PiB Cohen’s d = 1.781, [18F]AZD4694 Cohen’s d = 3.434), and hippocampus ([11C]PiB Cohen’s d = 1.320, [18F]AZD4694 Cohen’s d = 3.696). Higher binding was detected for [18F]AZD4694 compared to [11C]PiB in AD prefrontal, inferior parietal and posterior cingulate cortices, while binding in the hippocampus was comparable for both radioligands. Strong correlations between [18]AZD4694 and [11C]PiB were found in the prefrontal (R = 0.959, p < 0.0001), inferior parietal (R = 0.893, p < 0.0001), posterior cingulate (R = 0.838, p = 0.0006) cortices and hippocampus (R = 0.750, p < 0.0001). Bland–Altman analyses revealed strong agreement between [11C]PiB and [18F]AZD4694 in the prefrontal, inferior parietal, and posterior cingulate cortices, but lower agreement in the hippocampus. Displacement studies confirmed high binding affinity of PiB in all tissues, indicating that both amyloid-PET agents compete for the same binding sites. Conclusions: This head-to-head study provides evidence that while [18F]AZD4694 and [11C]PiB bindings are highly correlated with both tracers competing for the same binding sites, [18F]AZD4694 has a slightly higher effect size when comparing between neuropathologically-confirmed AD and HC brain tissues.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Brazilian Subjective Cognitive Decline (BRASCODE) Cohort: protocol and preliminary results
Background: Subjective Cognitive Decline (SCD) is a condition characterized by consistent cognitive complaints in cognitively unimpaired (CU) individuals and is associated with progressive cognitive impairment, especially in the context of Alzheimer’s disease (AD). We aimed to show the study protocol and the preliminary results of the Brazilian Subjective Cognitive Decline (BRASCODE) Cohort.Method: CU individuals with > 65 years old and cognitive complaints were recruited. Exclusion criteria were previous diagnosis of dementia, uncontrolled neuropsychiatric/clinical illness, or cerebrovascular disease. The assessment was performed exclusively by phone calls. It consisted of a brief cognitive (Modified Telephone Interview for Cognitive Status ‐ TICS‐M) and anxiety/depression screenings, in addition to the SCD‐scale (Figure 1).Result: Between March and November 2022, 52 SCD patients were included, 73.1% (n = 38) women. Their median interquartile range (IQR) age was 70 (68‐73) years old, with 16 (9.25‐19) years of formal education and median score of 28.5 (IQR 26,30) on Mini Mental State Examination (MMSE) (Table 1). Percentage of agreement on the presence of cognitive complaints between informants and patients was 38.5%. The main SCD‐plus criteria were the age at onset of SCD ≥ 60 years old (84.6%, n = 44) and concerns associated with SCD (78.8%, n = 41). The key findings of the neuropsychological assessment are reported in Table 2. Deficits were observed mainly in memory and executive functioning domains. Explorative analysis showed that Cognitive Reserve Scale scores correlated positively with MMSE (rho = 0.311; p = 0.02) and with formal education (rho = 0.541; p<0.001) and negatively with CDR‐sum of boxes (rho = ‐0.307; p = 0.03). The prevalence of APOE ε4 carriers was 29.8% (n = 14) and a dementia family history was more frequent in APOE ε4 carriers ‐ 12 (85.7%) ‐ than non‐carries, 12 (36.4%).Conclusion: The increase in the sample size, especially with individuals with low education, associated with AD biomarkers analysis and long‐term follow‐up may bring valuable information about the progression of SCD to cognitive decline in Brazil. We estimate that a total of 150 individuals will be included by the end of 2023.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessBrazilian Subjective Cognitive Decline (BRASCODE) Cohort: protocol and preliminary results
Background: Subjective Cognitive Decline (SCD) is a condition characterized by consistent cognitive complaints in cognitively unimpaired (CU) individuals and is associated with progressive cognitive impairment, especially in the context of Alzheimer’s disease (AD). We aimed to show the study protocol and the preliminary results of the Brazilian Subjective Cognitive Decline (BRASCODE) Cohort.Method: CU individuals with > 65 years old and cognitive complaints were recruited. Exclusion criteria were previous diagnosis of dementia, uncontrolled neuropsychiatric/clinical illness, or cerebrovascular disease. The assessment was performed exclusively by phone calls. It consisted of a brief cognitive (Modified Telephone Interview for Cognitive Status ‐ TICS‐M) and anxiety/depression screenings, in addition to the SCD‐scale (Figure 1).Result: Between March and November 2022, 52 SCD patients were included, 73.1% (n = 38) women. Their median interquartile range (IQR) age was 70 (68‐73) years old, with 16 (9.25‐19) years of formal education and median score of 28.5 (IQR 26,30) on Mini Mental State Examination (MMSE) (Table 1). Percentage of agreement on the presence of cognitive complaints between informants and patients was 38.5%. The main SCD‐plus criteria were the age at onset of SCD ≥ 60 years old (84.6%, n = 44) and concerns associated with SCD (78.8%, n = 41). The key findings of the neuropsychological assessment are reported in Table 2. Deficits were observed mainly in memory and executive functioning domains. Explorative analysis showed that Cognitive Reserve Scale scores correlated positively with MMSE (rho = 0.311; p = 0.02) and with formal education (rho = 0.541; p<0.001) and negatively with CDR‐sum of boxes (rho = ‐0.307; p = 0.03). The prevalence of APOE ε4 carriers was 29.8% (n = 14) and a dementia family history was more frequent in APOE ε4 carriers ‐ 12 (85.7%) ‐ than non‐carries, 12 (36.4%).Conclusion: The increase in the sample size, especially with individuals with low education, associated with AD biomarkers analysis and long‐term follow‐up may bring valuable information about the progression of SCD to cognitive decline in Brazil. We estimate that a total of 150 individuals will be included by the end of 2023.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Informant‐ and Patient‐reported Subjective Cognitive Decline: a preliminary analysis of the Brazilian Subjective Cognitive Decline Cohort
Background: Subjective Cognitive Decline (SCD) is characterized by self‐experience of deterioration in cognitive performance in cognitive unimpaired (CU) individuals and may represent a preclinical stage of neurodegenerative diseases, especially Alzheimer’s disease (AD). Informant‐reported cognitive complaints appear to increase the risk for cognitive decline in SCD individuals. We aimed to describe a preliminary analysis of informant‐ and patient‐reported SCD in the ongoing Brazilian SCD (BRASCODE) Cohort.Method: We are evaluating CU individuals older than 65 years‐old with cognitive complaints (and at least one SCD‐plus criteria). Biofluid‐ and imaging‐based biomarkers are being performed. Here, we evaluated the concordance of complaints between patients/informants and correlated them with patient’s sociodemographic and clinical variables. We described continuous variables as median (interquartile range, IQR) and categorical as frequencies. We performed a linear regression analysis with informant‐related complaints as the dependent variable, measured by the Subjective Cognitive Decline Scale, that ranges from 0 to 14, with scores ≥ 7 indicating complaint.Result: Between March and November 2022, 52 SCD patients were included, 70 (68‐73) years of age, 73.1% (n = 38) women. The median SCD‐patient and SCD‐informant scale was 8.5 (7 ‐ 9.25) and 5 (3 ‐ 7.25), respectively. The minority (20, 38.5%) of the informants agreed with the patients' cognitive complaints. The patients had a median of 3 (2 ‐ 4) SCD‐plus criteria, mainly age at onset of SCD ≥ 60 years‐old (16, 80%) and concerns associated with SCD (15, 75%) (Table 1). The SCD‐patient scale correlated negatively with patient age (rho = ‐ 0.362; p‐value = 0.008) and the SCD‐informant scale correlated negatively with patient education (rho = ‐ 0.349; p‐value = 0.01). In the linear regression analysis, the SCD‐informant scale was associated with the patient’s black race and education (p = 0.00141) (Table 2).Conclusion: In the ongoing BRASCODE cohort, the preliminary baseline analysis showed that most informants did not agree with the patients complaints, but education and race seem to influence the informant’s complaints. The increase in the sample size, AD biomarkers analysis, and follow‐up may bring valuable information about the relationship between patient’s and informant’s complaints.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessInformant‐ and Patient‐reported Subjective Cognitive Decline: a preliminary analysis of the Brazilian Subjective Cognitive Decline Cohort
Background: Subjective Cognitive Decline (SCD) is characterized by self‐experience of deterioration in cognitive performance in cognitive unimpaired (CU) individuals and may represent a preclinical stage of neurodegenerative diseases, especially Alzheimer’s disease (AD). Informant‐reported cognitive complaints appear to increase the risk for cognitive decline in SCD individuals. We aimed to describe a preliminary analysis of informant‐ and patient‐reported SCD in the ongoing Brazilian SCD (BRASCODE) Cohort.Method: We are evaluating CU individuals older than 65 years‐old with cognitive complaints (and at least one SCD‐plus criteria). Biofluid‐ and imaging‐based biomarkers are being performed. Here, we evaluated the concordance of complaints between patients/informants and correlated them with patient’s sociodemographic and clinical variables. We described continuous variables as median (interquartile range, IQR) and categorical as frequencies. We performed a linear regression analysis with informant‐related complaints as the dependent variable, measured by the Subjective Cognitive Decline Scale, that ranges from 0 to 14, with scores ≥ 7 indicating complaint.Result: Between March and November 2022, 52 SCD patients were included, 70 (68‐73) years of age, 73.1% (n = 38) women. The median SCD‐patient and SCD‐informant scale was 8.5 (7 ‐ 9.25) and 5 (3 ‐ 7.25), respectively. The minority (20, 38.5%) of the informants agreed with the patients' cognitive complaints. The patients had a median of 3 (2 ‐ 4) SCD‐plus criteria, mainly age at onset of SCD ≥ 60 years‐old (16, 80%) and concerns associated with SCD (15, 75%) (Table 1). The SCD‐patient scale correlated negatively with patient age (rho = ‐ 0.362; p‐value = 0.008) and the SCD‐informant scale correlated negatively with patient education (rho = ‐ 0.349; p‐value = 0.01). In the linear regression analysis, the SCD‐informant scale was associated with the patient’s black race and education (p = 0.00141) (Table 2).Conclusion: In the ongoing BRASCODE cohort, the preliminary baseline analysis showed that most informants did not agree with the patients complaints, but education and race seem to influence the informant’s complaints. The increase in the sample size, AD biomarkers analysis, and follow‐up may bring valuable information about the relationship between patient’s and informant’s complaints.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S19)
Analysis of the screening process in the Brazilian Subjective Cognitive Decline Cohort
Background: Subjective Cognitive Decline (SCD) is conceptualized as cognitive complaints in cognitively unimpaired (CU) individuals and is associated with progressive cognitive decline. Recruiting these individuals can be challenging, especially due to the low education levels and limited access to information by a portion of the Brazilian population.Objective: We aimed to analyze the profile of the screened individuals during the recruitment process in the ongoing Brazilian Subjective Cognitive Decline (BRASCODE) Cohort at the Hospital de Clínicas de Porto Alegre (HCPA), Southern Brazil.Methods: We analyzed the sociodemographic characteristics of the screened individuals recruited predominantly through social media and newspaper invitation. This study evaluated CU individuals aged 65+ years‐old with cognitive complaints. Exclusion criteria were the presence of uncontrolled psychiatric/clinical illness, cerebrovascular disease, and the use of psychotropic drugs. The recruitment was carried out exclusively by phone calls in two phases. In the first one, the exclusion criteria were applied and, in the second, the following scales were performed: Modified Telephone Interview for Cognitive Status (TICS‐M); Generalized Anxiety Disorder Assessment (GAD‐2); Geriatric Depression Scale; and the Subjective Cognitive Decline Scale.Results: From February to December 2022, 406 individuals were recruited. Most were women (74.6%; n = 303), with a median (SD) age of 71.6 (5.8) years‐old and 11 (5.2) years of formal education. The main reasons for exclusion in phone call 1 were clinical illness (39.9%; n = 59) and cerebrovascular disease (10.1%; n = 15). In those individuals evaluated in the phone call 2 (62.3%; n = 256), most were excluded because presented TICS‐M score below cut‐off (31.6%; n = 80), absence of cognitive complaints (29.6%; n = 75), and GAD‐2 (7%; n = 18) and GDS (3.5%; n = 9) scores above the cut‐off (Figure 1). Only 74 (18.2%) individuals were included in the cohort.Conclusion: The high screening failure seen in our study and the predominance of women with high educational level reveal the difficulty in screening SCD individuals and indicate the need for alternative recruitment methods, especially in a setting with low education.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S19)
Open AccessAnalysis of the screening process in the Brazilian Subjective Cognitive Decline Cohort
Background: Subjective Cognitive Decline (SCD) is conceptualized as cognitive complaints in cognitively unimpaired (CU) individuals and is associated with progressive cognitive decline. Recruiting these individuals can be challenging, especially due to the low education levels and limited access to information by a portion of the Brazilian population.Objective: We aimed to analyze the profile of the screened individuals during the recruitment process in the ongoing Brazilian Subjective Cognitive Decline (BRASCODE) Cohort at the Hospital de Clínicas de Porto Alegre (HCPA), Southern Brazil.Methods: We analyzed the sociodemographic characteristics of the screened individuals recruited predominantly through social media and newspaper invitation. This study evaluated CU individuals aged 65+ years‐old with cognitive complaints. Exclusion criteria were the presence of uncontrolled psychiatric/clinical illness, cerebrovascular disease, and the use of psychotropic drugs. The recruitment was carried out exclusively by phone calls in two phases. In the first one, the exclusion criteria were applied and, in the second, the following scales were performed: Modified Telephone Interview for Cognitive Status (TICS‐M); Generalized Anxiety Disorder Assessment (GAD‐2); Geriatric Depression Scale; and the Subjective Cognitive Decline Scale.Results: From February to December 2022, 406 individuals were recruited. Most were women (74.6%; n = 303), with a median (SD) age of 71.6 (5.8) years‐old and 11 (5.2) years of formal education. The main reasons for exclusion in phone call 1 were clinical illness (39.9%; n = 59) and cerebrovascular disease (10.1%; n = 15). In those individuals evaluated in the phone call 2 (62.3%; n = 256), most were excluded because presented TICS‐M score below cut‐off (31.6%; n = 80), absence of cognitive complaints (29.6%; n = 75), and GAD‐2 (7%; n = 18) and GDS (3.5%; n = 9) scores above the cut‐off (Figure 1). Only 74 (18.2%) individuals were included in the cohort.Conclusion: The high screening failure seen in our study and the predominance of women with high educational level reveal the difficulty in screening SCD individuals and indicate the need for alternative recruitment methods, especially in a setting with low education.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
A systematic evaluation of cortical GABA levels in transgenic mouse models of amyloid
Background: Rodent models that overexpress mutations in the amyloid precursor protein (APP) and presenilin 1 (PSEN1) genes have been widely applied in Alzheimer’s disease (AD) research. These models classically present amyloid plaque deposition in cortical and hippocampal areas and neurotransmission changes. Although amyloid‐related glutamatergic abnormalities have been extensively described, little is known about its effects on the GABAergic system. Thus, we aimed to examine GABA levels in the cortex of two transgenic amyloid mouse models.Method: We systematically reviewed the literature following the PRISMA 2020 guidelines. PubMed and Web of Science databases were searched for studies reporting GABA levels in the cortex of APPswe/PSEN1dE9 and Tg2576 mice. We opted to evaluate only animals with mature amyloid plaques in their cortices, according to each mouse model previous characterization.Result: The search identified 3576 papers. Seven records met the inclusion criteria (Tg2576: n = 21, mean age ± standard deviation (SD) = 14.7 ± 3.7 months; controls: n = 21; APPswe/PSEN1dE9: n = 25, mean age ± SD = 8.5 ± 4.1 months; controls: n = 25). Five out of seven results reported non‐significant differences in the GABA levels in multiple cortical regions, such as the frontal, pre‐frontal, and rhinal cortices of the Tg2576 mouse model, but two studies described that GABA is significantly decreased. Furthermore, all studies with the APP/PSEN1 model consistently reported decreased cortical GABA levels. Figure 1 provides a summary of our findings.Conclusion: Our results suggest that APP and PSEN1 mutations may contribute to the decrease in the levels of GABA in cortical regions of amyloid models. Future meta‐analyses and clinical studies are needed to ascertain the consistency of the reported results.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessA systematic evaluation of cortical GABA levels in transgenic mouse models of amyloid
Background: Rodent models that overexpress mutations in the amyloid precursor protein (APP) and presenilin 1 (PSEN1) genes have been widely applied in Alzheimer’s disease (AD) research. These models classically present amyloid plaque deposition in cortical and hippocampal areas and neurotransmission changes. Although amyloid‐related glutamatergic abnormalities have been extensively described, little is known about its effects on the GABAergic system. Thus, we aimed to examine GABA levels in the cortex of two transgenic amyloid mouse models.Method: We systematically reviewed the literature following the PRISMA 2020 guidelines. PubMed and Web of Science databases were searched for studies reporting GABA levels in the cortex of APPswe/PSEN1dE9 and Tg2576 mice. We opted to evaluate only animals with mature amyloid plaques in their cortices, according to each mouse model previous characterization.Result: The search identified 3576 papers. Seven records met the inclusion criteria (Tg2576: n = 21, mean age ± standard deviation (SD) = 14.7 ± 3.7 months; controls: n = 21; APPswe/PSEN1dE9: n = 25, mean age ± SD = 8.5 ± 4.1 months; controls: n = 25). Five out of seven results reported non‐significant differences in the GABA levels in multiple cortical regions, such as the frontal, pre‐frontal, and rhinal cortices of the Tg2576 mouse model, but two studies described that GABA is significantly decreased. Furthermore, all studies with the APP/PSEN1 model consistently reported decreased cortical GABA levels. Figure 1 provides a summary of our findings.Conclusion: Our results suggest that APP and PSEN1 mutations may contribute to the decrease in the levels of GABA in cortical regions of amyloid models. Future meta‐analyses and clinical studies are needed to ascertain the consistency of the reported results.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
The relationship between [18F]FDG‐PET signal and key‐players of brain glucose metabolism
Background: Neuronal activity is supported by activity‐dependent lactate production from astrocytes, as postulated by the astrocyte–neuron lactate shuttle (ANLS) hypothesis. Indeed, astrocytic glutamate uptake is a main trigger for brain glucose consumption. [18F]fluorodeoxyglucose (FDG)‐PET showing a hypometabolic signature has been used as an index of neurodegeneration in Alzheimer’s disease (AD). In the early stages of the disease, soluble amyloid‐beta (Aβ) has been associated with neuronal hyperactivity due to decreased astrocytic glutamate uptake. It is hypothesized that this phenomenon occurs especially in regions with high ongoing baseline activity. Over time, neurodegeneration and hypometabolism in such regions may contribute to the progress of the AD continuum. Thus, we investigated whether the [18F]FDG‐PET signal in typical hypometabolic regions in AD is associated with the expression of ANLS transporters and enzymes in the healthy brain.Method: Gene expression of GLUT1, GLUT3, MCT1, MCT2, MCT4, LDHA, and LDHB (ANLS genes) from postmortem brain tissue of healthy individuals were obtained from the Allen Human Brain Atlas. [18F]FDG‐PET data from cognitively unimpaired individuals were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Pearson correlations were performed between the mean gene expression and the mean [18F]FDG‐PET SUVr across typically hypometabolic brain regions in AD (precuneus, angular and temporal gyri, and parietal and cingulate regions) and non‐vulnerable regions (uncorrected p‐value < 0.05).Results: The expression of ANLS genes had a stronger positive correlation with [18F]FDG‐PET SUVr across the AD hypometabolic regions than the non‐vulnerable regions (p < 0.05). Of note, the astrocytic glucose transporter GLUT1 presented a stronger correlation with [18F]FDG‐PET than the neuronal transporter GLUT3 in AD‐vulnerable regions. Figure 1 presents all correlations.Conclusion: Our results show that the physiological expression of transporters and enzymes responsible for the brain glucose metabolism correlate more with the [18F]FDG‐PET signal in typical brain regions of the AD hypometabolic signature. This suggests these regions present a higher baseline activity and may be more susceptible to Aβ‐induced hyperactivation in early AD, which could lead to a bioenergetic collapse in later disease stages, as shown in the [18F]FDG‐PET of AD individuals.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S16)
Open AccessThe relationship between [18F]FDG‐PET signal and key‐players of brain glucose metabolism
Background: Neuronal activity is supported by activity‐dependent lactate production from astrocytes, as postulated by the astrocyte–neuron lactate shuttle (ANLS) hypothesis. Indeed, astrocytic glutamate uptake is a main trigger for brain glucose consumption. [18F]fluorodeoxyglucose (FDG)‐PET showing a hypometabolic signature has been used as an index of neurodegeneration in Alzheimer’s disease (AD). In the early stages of the disease, soluble amyloid‐beta (Aβ) has been associated with neuronal hyperactivity due to decreased astrocytic glutamate uptake. It is hypothesized that this phenomenon occurs especially in regions with high ongoing baseline activity. Over time, neurodegeneration and hypometabolism in such regions may contribute to the progress of the AD continuum. Thus, we investigated whether the [18F]FDG‐PET signal in typical hypometabolic regions in AD is associated with the expression of ANLS transporters and enzymes in the healthy brain.Method: Gene expression of GLUT1, GLUT3, MCT1, MCT2, MCT4, LDHA, and LDHB (ANLS genes) from postmortem brain tissue of healthy individuals were obtained from the Allen Human Brain Atlas. [18F]FDG‐PET data from cognitively unimpaired individuals were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Pearson correlations were performed between the mean gene expression and the mean [18F]FDG‐PET SUVr across typically hypometabolic brain regions in AD (precuneus, angular and temporal gyri, and parietal and cingulate regions) and non‐vulnerable regions (uncorrected p‐value < 0.05).Results: The expression of ANLS genes had a stronger positive correlation with [18F]FDG‐PET SUVr across the AD hypometabolic regions than the non‐vulnerable regions (p < 0.05). Of note, the astrocytic glucose transporter GLUT1 presented a stronger correlation with [18F]FDG‐PET than the neuronal transporter GLUT3 in AD‐vulnerable regions. Figure 1 presents all correlations.Conclusion: Our results show that the physiological expression of transporters and enzymes responsible for the brain glucose metabolism correlate more with the [18F]FDG‐PET signal in typical brain regions of the AD hypometabolic signature. This suggests these regions present a higher baseline activity and may be more susceptible to Aβ‐induced hyperactivation in early AD, which could lead to a bioenergetic collapse in later disease stages, as shown in the [18F]FDG‐PET of AD individuals.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Progressive dysregulation of circular RNAs in the hippocampus of a transgenic mouse model of amyloidosis
Background: Circular RNAs (circRNAs) are a class of RNAs that act as transcriptional regulators. They have a circular structure and are produced from back‐splicing events, which makes them more stable than linear RNAs. In Alzheimer’s disease (AD), the role of circRNAs remains elusive. Here, we aimed to evaluate whether the transcription of circRNAs is altered in the hippocampus, a region highly vulnerable to AD, of a transgenic amyloid mouse model.Method: We selected hippocampal RNA‐sequencing or microarray datasets of circRNAs of the APPswe/PSEN1dE9, a widely used transgenic amyloid mouse model, from the NCBI databases. CircRNAs were detected with the CIRI2 algorithm by using the gene symbol of the parent transcript and the transcript ID. We identified the differently expressed circRNAs between APPswe/PSEN1dE9 and age‐matched wild‐types using the DESeq2 method (p‐value < 0.01). The packages UpSetR and VennDiagram were used to uncover the circRNAs commonly altered between the studies. All analyses were performed in R.Result: From 12 databases, three had hippocampal circRNA data of 4, 6, and 8‐month‐old APPswe/PSEN1dE9 mice (GSE166393; GSE158995; and PRJNA712946, n = 3 per group). Amyloid‐beta (Aβ) starts to deposit at six months in the APPswe/PSEN1dE9 hippocampus. The number of dysregulated circRNAs increased with age: 41 (4‐month‐old), 82 (6‐month‐old), and 425 (8‐month‐old) (Figure 1). Interestingly, only one circRNA was shared between the three studies at all time points, originating from the CCDC141 gene. Additionally, 15 circRNAs were shared in at least two ages, such as CD2AP, FMN1, HOMER1, IL1RAP, NDST3, and TET1 (Please, see the full list of intersections in Figure 2). By dividing groups into pre‐plaque (4‐month‐old) and amyloid (6 and 8‐month‐old) phases, we found that four altered circRNAs were shared in both stages, 37 exclusively in pre‐amyloid stage and 490 in amyloid stage (Figure 3).Conclusion: Our results demonstrate an increasing dysregulation in circRNAs profiles in the hippocampus of the APP/PS1 mice. Considering the role of circRNAs as transcriptional regulators, one could argue that these progressive changes may impact gene expression in AD‐related brain regions.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessProgressive dysregulation of circular RNAs in the hippocampus of a transgenic mouse model of amyloidosis
Background: Circular RNAs (circRNAs) are a class of RNAs that act as transcriptional regulators. They have a circular structure and are produced from back‐splicing events, which makes them more stable than linear RNAs. In Alzheimer’s disease (AD), the role of circRNAs remains elusive. Here, we aimed to evaluate whether the transcription of circRNAs is altered in the hippocampus, a region highly vulnerable to AD, of a transgenic amyloid mouse model.Method: We selected hippocampal RNA‐sequencing or microarray datasets of circRNAs of the APPswe/PSEN1dE9, a widely used transgenic amyloid mouse model, from the NCBI databases. CircRNAs were detected with the CIRI2 algorithm by using the gene symbol of the parent transcript and the transcript ID. We identified the differently expressed circRNAs between APPswe/PSEN1dE9 and age‐matched wild‐types using the DESeq2 method (p‐value < 0.01). The packages UpSetR and VennDiagram were used to uncover the circRNAs commonly altered between the studies. All analyses were performed in R.Result: From 12 databases, three had hippocampal circRNA data of 4, 6, and 8‐month‐old APPswe/PSEN1dE9 mice (GSE166393; GSE158995; and PRJNA712946, n = 3 per group). Amyloid‐beta (Aβ) starts to deposit at six months in the APPswe/PSEN1dE9 hippocampus. The number of dysregulated circRNAs increased with age: 41 (4‐month‐old), 82 (6‐month‐old), and 425 (8‐month‐old) (Figure 1). Interestingly, only one circRNA was shared between the three studies at all time points, originating from the CCDC141 gene. Additionally, 15 circRNAs were shared in at least two ages, such as CD2AP, FMN1, HOMER1, IL1RAP, NDST3, and TET1 (Please, see the full list of intersections in Figure 2). By dividing groups into pre‐plaque (4‐month‐old) and amyloid (6 and 8‐month‐old) phases, we found that four altered circRNAs were shared in both stages, 37 exclusively in pre‐amyloid stage and 490 in amyloid stage (Figure 3).Conclusion: Our results demonstrate an increasing dysregulation in circRNAs profiles in the hippocampus of the APP/PS1 mice. Considering the role of circRNAs as transcriptional regulators, one could argue that these progressive changes may impact gene expression in AD‐related brain regions.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau
Background: Alzheimer’s disease (AD) is characterized by the extracellular accumulation of amyloid‐β (Aβ) plaques and neuronal deposition of tau tangles, mainly in cortical regions and the hippocampus. Beyond these neuropathological hallmarks, it is suggested that neurotransmission dysfunctions, such as in the γ‐aminobutyric acid (GABA)ergic system, contribute to AD pathophysiology. However, the impact of Aβ and tau in the GABAergic system is still unknown. Thus, we aimed to examine GABA levels in the hippocampus of transgenic mouse models of Aβ and tau.Method: We systematically reviewed the literature following the PRISMA 2020 guidelines. We searched PubMed and Web of Science databases for studies reporting GABA levels in the 3xTg‐AD and 5xFAD mouse models. These models present APP and PSEN1 mutations, but the 3xTg‐AD also harbors the MAPT P310L tau mutation, which is found in frontotemporal dementia.Result: The search identified 3,576 articles. Six met the inclusion criteria (n = 26 3xTg‐AD and 26 wild‐type (WT); n = 16 5xFAD and 17 WT). The studies reported no significant differences in the levels of GABA in the hippocampus of 3xTg‐AD mice compared to their WT, but GABA levels decreased as a function of age. By contrast, the 5xFAD mouse model presented higher levels of GABA than their WT littermates.Conclusion: Here, we show no significant changes in GABA levels in the hippocampus of 3xTg‐AD mice, whereas the levels of GABA were increased in the 5xFAD. Interestingly, the model harboring APP, PSEN1, and MAPT P310L mutations does not present changes in hippocampal levels of GABA. Our results suggest that Aβ alters GABA levels in the hippocampus, which may be an early change in AD. In addition, hippocampal GABAergic changes seem sensitive to different pathological features of AD.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessA systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau
Background: Alzheimer’s disease (AD) is characterized by the extracellular accumulation of amyloid‐β (Aβ) plaques and neuronal deposition of tau tangles, mainly in cortical regions and the hippocampus. Beyond these neuropathological hallmarks, it is suggested that neurotransmission dysfunctions, such as in the γ‐aminobutyric acid (GABA)ergic system, contribute to AD pathophysiology. However, the impact of Aβ and tau in the GABAergic system is still unknown. Thus, we aimed to examine GABA levels in the hippocampus of transgenic mouse models of Aβ and tau.Method: We systematically reviewed the literature following the PRISMA 2020 guidelines. We searched PubMed and Web of Science databases for studies reporting GABA levels in the 3xTg‐AD and 5xFAD mouse models. These models present APP and PSEN1 mutations, but the 3xTg‐AD also harbors the MAPT P310L tau mutation, which is found in frontotemporal dementia.Result: The search identified 3,576 articles. Six met the inclusion criteria (n = 26 3xTg‐AD and 26 wild‐type (WT); n = 16 5xFAD and 17 WT). The studies reported no significant differences in the levels of GABA in the hippocampus of 3xTg‐AD mice compared to their WT, but GABA levels decreased as a function of age. By contrast, the 5xFAD mouse model presented higher levels of GABA than their WT littermates.Conclusion: Here, we show no significant changes in GABA levels in the hippocampus of 3xTg‐AD mice, whereas the levels of GABA were increased in the 5xFAD. Interestingly, the model harboring APP, PSEN1, and MAPT P310L mutations does not present changes in hippocampal levels of GABA. Our results suggest that Aβ alters GABA levels in the hippocampus, which may be an early change in AD. In addition, hippocampal GABAergic changes seem sensitive to different pathological features of AD.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
GABA transporters gene expression associates with [18F]FDG‐PET signal in regions typically hypometabolic in Alzheimer’s disease
Background: It is suggested that the [18F]fluorodeoxyglucose(FDG)‐PET signal reflects astrocyte and neuronal activity, with the excitatory glutamate uptake by astrocytes as the trigger for brain glucose metabolism. The inhibitory neurotransmitter γ‐aminobutyric acid (GABA) is taken up by neurons and astrocytes through the GABA transporters (GAT) 1 and 3. However, its role in the [18F]FDG‐PET signal in healthy aging and Alzheimer’s disease (AD) remains poorly investigated. Thus, we aimed to explore associations between neuronal and astrocytic GABA transporters gene expression with [18F]FDG‐PET in cognitively unimpaired (CU) and AD individuals.Method: We obtained [18F]FDG‐PET imaging data of CU and AD from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Table 1). GAT1 and GAT3 gene expression in the brain was obtained from the Allen Brain Atlas (Table 1, Figure 1). We extracted SUVr (pons as reference region) and mRNA values using the RMINC package and performed Pearson’s correlation to test the association between [18F]FDG‐PET and GABA transporters mRNA (p‐value < 0.05).Result: In brain regions typically hypometabolic in AD, we observed a strong positive association of [18F]FDG‐PET SUVr with GAT1 and GAT3 gene expression in CU (GAT1: r = 0.93; p < 0.0001; Figure 2A, GAT3: r = 0.94; p < 0.0001; Figure 2B) and AD individuals (GAT1: r = 0.9; p < 0.0001; Figure 2A, GAT3: r = 0.92; p < 0.0001; Figure 2B). By contrast, in brain regions typically resilient, we found a weak correlation with CU individuals (GAT1: r = 0.32; p = 0.016; Figure 2C, GAT3: r = 0.26; p = 0.04; Figure 2D) and no significant correlation in AD patients (GAT1: r = 0.24; p = 0.07; Figure 2C, GAT3: r = 0.24; p = 0.059; Figure 2D).Conclusion: Our results demonstrate a significant strong positive association between [18F]FDG‐PET SUVr and GABA transporters gene expression in CU and AD in hypometabolic regions. These findings suggest that GABA transporters are involved with brain glucose metabolism in regions classically vulnerable to AD pathology.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessGABA transporters gene expression associates with [18F]FDG‐PET signal in regions typically hypometabolic in Alzheimer’s disease
Background: It is suggested that the [18F]fluorodeoxyglucose(FDG)‐PET signal reflects astrocyte and neuronal activity, with the excitatory glutamate uptake by astrocytes as the trigger for brain glucose metabolism. The inhibitory neurotransmitter γ‐aminobutyric acid (GABA) is taken up by neurons and astrocytes through the GABA transporters (GAT) 1 and 3. However, its role in the [18F]FDG‐PET signal in healthy aging and Alzheimer’s disease (AD) remains poorly investigated. Thus, we aimed to explore associations between neuronal and astrocytic GABA transporters gene expression with [18F]FDG‐PET in cognitively unimpaired (CU) and AD individuals.Method: We obtained [18F]FDG‐PET imaging data of CU and AD from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (Table 1). GAT1 and GAT3 gene expression in the brain was obtained from the Allen Brain Atlas (Table 1, Figure 1). We extracted SUVr (pons as reference region) and mRNA values using the RMINC package and performed Pearson’s correlation to test the association between [18F]FDG‐PET and GABA transporters mRNA (p‐value < 0.05).Result: In brain regions typically hypometabolic in AD, we observed a strong positive association of [18F]FDG‐PET SUVr with GAT1 and GAT3 gene expression in CU (GAT1: r = 0.93; p < 0.0001; Figure 2A, GAT3: r = 0.94; p < 0.0001; Figure 2B) and AD individuals (GAT1: r = 0.9; p < 0.0001; Figure 2A, GAT3: r = 0.92; p < 0.0001; Figure 2B). By contrast, in brain regions typically resilient, we found a weak correlation with CU individuals (GAT1: r = 0.32; p = 0.016; Figure 2C, GAT3: r = 0.26; p = 0.04; Figure 2D) and no significant correlation in AD patients (GAT1: r = 0.24; p = 0.07; Figure 2C, GAT3: r = 0.24; p = 0.059; Figure 2D).Conclusion: Our results demonstrate a significant strong positive association between [18F]FDG‐PET SUVr and GABA transporters gene expression in CU and AD in hypometabolic regions. These findings suggest that GABA transporters are involved with brain glucose metabolism in regions classically vulnerable to AD pathology.